• About Us
    • About Us
    • Corporate Strategy
    • Our Vision and Values
    • Research & Development
    • Operations
    • Business Development
    • Awards and Grants
  • Announcements
  • Our Team
    • Management Team
    • Scientific Team
    • Scientific Advisory Board
  • Portfolio
    • Our Portfolio
    • Lupuzor™ & Lupus
    • Autoimmunity
    • Metabolism
    • Anti-infectives
    • Cancer
  • Investors
    • Investor Relations
    • AIM Rule 26 Information
    • Euronext Growth
    • Regulatory News
    • Market Commentary
    • Share Price
    • Analyst Research
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Interviews
    • Professional Advisers
    • Email Alerts
  • Media
    • Events and Conferences
    • Media Room
    • Interviews
    • Scientific Publications
  • Contact Us
Archives
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
December 03, 2020

ImmuPharma to present at Biotech Showcase™ Digital 2021

Read More
November 30, 2020

Total Share Capital Notification

Read More
November 26, 2020

Grant of Share Options & PDMR dealing

Read More
November 24, 2020

Conversion of Convertible Security

Read More
November 23, 2020

Conversion of Convertible Security

Read More
November 20, 2020

FDA confirms 4 December 2020 for Type ‘A’ meeting to discuss guidance on forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients

Read More
November 19, 2020

Total Share Capital Notification

Read More
November 10, 2020

Update on submission to the FDA for the forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients

Read More
September 30, 2020

Total Share Capital Notification Admission to trading on Euronext Growth Brussels of newly issued ordinary shares

Read More
September 30, 2020

INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2020

Read More
September 29, 2020

Share Subscription into Incanthera plc (“Incanthera”)

Read More
September 22, 2020

Repayment of Convertible Security – Lind Global Macro Fund, LP

Read More
  • 1
  • 2
  • 3
  • 4
Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2021 | All rights reserved

Cookies

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the Cookie Policy